Compass Therapeutics (CMPX) Stock Forecast & Price Target

Compass Therapeutics is supported by a compelling combination of clinical signal, platform optionality, and a manageable cash runway. Tovecimig plus paclitaxel improved median PFS to 4.7 months versus 2.6 months for paclitaxel alone, with a hazard ratio of 0.44 and a 56% reduction in progression risk, while also clearing the roughly 4.0-month ABC-06 FOLFOX benchmark. With $179.9MM of cash, expected 4Q26 data for CTX-8371 and CTX-10726, and an estimated end of 2Q27 cash balance of $84.7MM, the company appears positioned to advance its pipeline through a regulatory path that remains promising despite no near-term revenue.

Compass Therapeutics is burdened by the core risks of clinical-stage biotechnology: expensive development, a high historical failure rate, intense competition, and heavy dependence on FDA review and approval. Although COMPANION-002 met its primary endpoint on ORR and showed PFS with a hazard ratio of 0.44, the numerically worse ITT overall survival and crossover complexity leave tovecimig vulnerable if the FDA insists on a new survival-benefit study, materially raising the regulatory bar. With tovecimig removed from the model, the outlook weakens further despite potential catalysts in 4Q:26 for CTX-8371 and CTX-10726, because the company still lacks differentiated late-stage proof and remains exposed to sector-wide volatility.